Psychedelic medicine options are becoming more widely available, with ketamine currently legal nationwide, psilocybin legal for adult use in Oregon now and Colorado soon, and MDMA growing nearer to FDA approval. However, there are a number of challenges to be overcome to fully integrate these medicines into our current medical model, including education of patients, training of clinicians, getting insurance to cover the therapies, and finding ways to establish safeguards and standards for psychedelic therapeutics. This talk dives into the specifics of each of those challenges and discusses how each is being addressed.
